Fatemeh Rezaei-Tazangi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fatemeh Rezaei-Tazangi has a total of 244 co-authors. Here are the top co-authors by number of shared publications:
- Reza Arefnezhad
Student Research Committee Fasa University of Medical Sciences Fasa Iran
17 shared publications Marziye Ranjbar Tavakoli
Pharmaceutical Sciences and Cosmetic Products Research Center Kerman University of Medical Sciences Kerman Iran
8 shared publicationsReza Arefnezhad
School of Medicine Shiraz University of Medical Sciences Shiraz Iran
8 shared publicationsAmir Modarresi Chahardehi
7 shared publicationsHossein Fatemian
School of Medicine Shiraz University of Medical Sciences Shiraz Iran
7 shared publicationsReza Nasiri
School of Medicine Shiraz University of Medical Sciences Shiraz Iran
7 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Wiley in Health Science Reports
- Vol. 9  (8)
The Therapeutic Potential of Stem Cell Therapy for DoxorubicinâInduced Cardiotoxicity: A Narrative Review
Background and Aims: Doxorubicin (DOX) is a potent anthracycline chemotherapeutic agent whose clinical utility is significantly constrained by severe side effects, most notably DOXâinduced cardiotoxicity (DIC). Pathophysiological mechanisms of DIC include oxidative stress, mitochondrial dysfunction, programmed cell death, and inflammation. Given the therapeutic potential of stem cell technology, this narrative review aims to summarize current evidence regarding the use of various stem cell types, particularly mesenchymal stem cells (MSCs), as a potential treatment for DIC. Methods: This study conducted a comprehensive review of the literature concerning stem cellâbased therapies in the context of DIC. We evaluated evidence regarding both pluripotent stem cells (including embryonic and induced pluripotent stem cells) and multipotent adult stem cells (such as bone marrow, adipose, and umbilical cordâderived MSCs) to assess their role in mitigating DOXâinduced cardiac damage. Results: Current research indicates that stem cells, particularly MSCs, possess significant regenerative capabilities that may counteract the multifaceted pathophysiology of DIC. Evidence suggests that these cells can modulate inflammatory responses, alleviate oxidative stress, and support mitochondrial repair in damaged cardiac tissue, thereby offering a promising strategy to protect against or reverse chemotherapyâinduced heart injury. Conclusion: Stem cellâbased therapy represents a promising and innovative frontier for the management of DOXâinduced cardiotoxicity. While preclinical and emerging data highlight the therapeutic potential of MSCs in cardiac protection, further standardized research is required to fully elucidate their mechanisms and ensure clinical safety and efficacy for patients undergoing chemotherapy.
- 29 July 2026
- Published by Wiley in Health Science Reports
- Vol. 9  (8)
Open AccessThe Therapeutic Potential of Stem Cell Therapy for DoxorubicinâInduced Cardiotoxicity: A Narrative Review
Background and Aims: Doxorubicin (DOX) is a potent anthracycline chemotherapeutic agent whose clinical utility is significantly constrained by severe side effects, most notably DOXâinduced cardiotoxicity (DIC). Pathophysiological mechanisms of DIC include oxidative stress, mitochondrial dysfunction, programmed cell death, and inflammation. Given the therapeutic potential of stem cell technology, this narrative review aims to summarize current evidence regarding the use of various stem cell types, particularly mesenchymal stem cells (MSCs), as a potential treatment for DIC. Methods: This study conducted a comprehensive review of the literature concerning stem cellâbased therapies in the context of DIC. We evaluated evidence regarding both pluripotent stem cells (including embryonic and induced pluripotent stem cells) and multipotent adult stem cells (such as bone marrow, adipose, and umbilical cordâderived MSCs) to assess their role in mitigating DOXâinduced cardiac damage. Results: Current research indicates that stem cells, particularly MSCs, possess significant regenerative capabilities that may counteract the multifaceted pathophysiology of DIC. Evidence suggests that these cells can modulate inflammatory responses, alleviate oxidative stress, and support mitochondrial repair in damaged cardiac tissue, thereby offering a promising strategy to protect against or reverse chemotherapyâinduced heart injury. Conclusion: Stem cellâbased therapy represents a promising and innovative frontier for the management of DOXâinduced cardiotoxicity. While preclinical and emerging data highlight the therapeutic potential of MSCs in cardiac protection, further standardized research is required to fully elucidate their mechanisms and ensure clinical safety and efficacy for patients undergoing chemotherapy.
- Open Access
- 6 July 2026
- Published by Wiley in Health Science Reports
- Vol. 9  (7) , e72685
Unlocking the Cardioprotective Action of Human Amniotic Mesenchymal Stem Cells: A Review of the Current Documents
Background and Aims: Cardiovascular diseases (CVDs), such as heart failure (HF), myocardial ischemicâreperfusion injury (MIRI), and myocardial infarction (MI), are defined as one of the most known causes of mortality and morbidity worldwide, responsible for 30% of global death rate. The etiologic factors for CVDs have not been exactly comprehended; however, a number of modifiable and nonmodifiable risk factors have been recognized, like smoking, physical activity, and the history of some diseases (e.g., hyperlipidemia, hypertension, and obesity). Although the current therapeutic approaches for these diseases, which are on the basis of conventional pharmacotherapy and surgery, have been largely effective in dwindling mortality and alleviating symptoms, the presence of serious side effects and injury to the different body organs and restricted clinical application are the main barriers of these methods. Therefore, there is an unmet need to recommend alternative and effective strategies with the minimum side effects for CVDs. Results: Recently, mesenchymal stem cell (MSC)âbased therapies have opened a new window to patients with diverse health problems. MSCs can be isolated from different sources, for example, adipose tissue, bone marrow, umbilical cord, amniotic membrane, and amniotic fluid, and have reflected remarkable pharmacological and biological abilities. An increasing body of evidence has paid special attention to MSCs derived from the amniotic membrane and amniotic fluid for treating healthâthreatening conditions, particularly CVDs, in light of their safety and facility in collecting without considerable ethical issues. Conclusion: This narrative review delves into the cardioprotective potential of human amniotic mesenchymal stem cells against the three main cardiovascular disorders with high lethality, including HF, MIRI, and MI, with a mechanistic insight.
- 6 July 2026
- Published by Wiley in Health Science Reports
- Vol. 9  (7) , e72685
Open AccessUnlocking the Cardioprotective Action of Human Amniotic Mesenchymal Stem Cells: A Review of the Current Documents
Background and Aims: Cardiovascular diseases (CVDs), such as heart failure (HF), myocardial ischemicâreperfusion injury (MIRI), and myocardial infarction (MI), are defined as one of the most known causes of mortality and morbidity worldwide, responsible for 30% of global death rate. The etiologic factors for CVDs have not been exactly comprehended; however, a number of modifiable and nonmodifiable risk factors have been recognized, like smoking, physical activity, and the history of some diseases (e.g., hyperlipidemia, hypertension, and obesity). Although the current therapeutic approaches for these diseases, which are on the basis of conventional pharmacotherapy and surgery, have been largely effective in dwindling mortality and alleviating symptoms, the presence of serious side effects and injury to the different body organs and restricted clinical application are the main barriers of these methods. Therefore, there is an unmet need to recommend alternative and effective strategies with the minimum side effects for CVDs. Results: Recently, mesenchymal stem cell (MSC)âbased therapies have opened a new window to patients with diverse health problems. MSCs can be isolated from different sources, for example, adipose tissue, bone marrow, umbilical cord, amniotic membrane, and amniotic fluid, and have reflected remarkable pharmacological and biological abilities. An increasing body of evidence has paid special attention to MSCs derived from the amniotic membrane and amniotic fluid for treating healthâthreatening conditions, particularly CVDs, in light of their safety and facility in collecting without considerable ethical issues. Conclusion: This narrative review delves into the cardioprotective potential of human amniotic mesenchymal stem cells against the three main cardiovascular disorders with high lethality, including HF, MIRI, and MI, with a mechanistic insight.
- Open Access
- 30 June 2026
- Published by Wiley in Health Science Reports
- Vol. 9  (7)
Lessons From Astaxanthin Therapy to Combat Oral Premalignant and Malignant Lesions: A Narrative Review
Background and Aims: Oral cancer is one of the most common head and neck malignancies and remains associated with high morbidity, mortality, and treatmentârelated toxicity. Despite advances in surgery, radiotherapy, and chemotherapy, there is still a need for safer adjunctive therapies with better therapeutic potential. Results: Astaxanthin, a natural lipophilic carotenoid, has gained attention because of its antioxidant, antiâinflammatory, and anticancer activities. The available evidence suggests that astaxanthin may suppress oral premalignant and malignant progression by inhibiting inflammation, oxidative stress, proliferation, invasion, angiogenesis, and survival signaling pathways, while promoting apoptosis and reactivating tumor suppressor mechanisms. Preclinical studies also indicate that astaxanthinâbased formulations may improve delivery efficiency and enhance antitumor effects in oral cancer models. Conclusion: Overall, astaxanthin appears to be a promising natural candidate for oral cancer prevention and treatment. However, most findings are based on preclinical studies, and further wellâdesigned clinical investigations are required to confirm its efficacy and safety.
- 30 June 2026
- Published by Wiley in Health Science Reports
- Vol. 9  (7)
Open AccessLessons From Astaxanthin Therapy to Combat Oral Premalignant and Malignant Lesions: A Narrative Review
Background and Aims: Oral cancer is one of the most common head and neck malignancies and remains associated with high morbidity, mortality, and treatmentârelated toxicity. Despite advances in surgery, radiotherapy, and chemotherapy, there is still a need for safer adjunctive therapies with better therapeutic potential. Results: Astaxanthin, a natural lipophilic carotenoid, has gained attention because of its antioxidant, antiâinflammatory, and anticancer activities. The available evidence suggests that astaxanthin may suppress oral premalignant and malignant progression by inhibiting inflammation, oxidative stress, proliferation, invasion, angiogenesis, and survival signaling pathways, while promoting apoptosis and reactivating tumor suppressor mechanisms. Preclinical studies also indicate that astaxanthinâbased formulations may improve delivery efficiency and enhance antitumor effects in oral cancer models. Conclusion: Overall, astaxanthin appears to be a promising natural candidate for oral cancer prevention and treatment. However, most findings are based on preclinical studies, and further wellâdesigned clinical investigations are required to confirm its efficacy and safety.
- Open Access
- 14 June 2026
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 21, 122-131
Unlocking the healing power of Berberine: A promising aid for multiple sclerosis
- 14 June 2026
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 21, 122-131
Open AccessUnlocking the healing power of Berberine: A promising aid for multiple sclerosis
- Open Access
- 28 February 2026
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 20, 694-702
Research trends in microRNAs in glioma tumors: A data-driven exploration using a bibliometric approach
- 28 February 2026
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 20, 694-702
Open AccessResearch trends in microRNAs in glioma tumors: A data-driven exploration using a bibliometric approach
- Open Access
- 28 February 2026
- Published by Wiley in Health Science Reports
- Vol. 9  (3)
Quercetin and Its NanoâBased Formulations Against Skin Cancer: A Narrative Review
Background: Skin cancer is one of the most prevalent malignancies worldwide, characterized by the abnormal growth of skin cells and significant clinical challenges. Conventional treatmentsâincluding surgery, chemotherapy, and radiotherapyâoften suffer from limitations such as adverse side effects, tumor resistance, and inadequate efficacy. In this context, natural compounds have garnered attention as alternative therapeutic agents. Quercetin, a flavonoid widely distributed in fruits and vegetables, is recognized for its antiâcancer, antiâinflammatory, and antioxidant properties. However, its clinical application is hindered by poor solubility, low bioavailability, and limited skin permeation. Recent advances in nanotechnology have led to the development of nanoâbased formulations that can enhance the pharmacological performance of quercetin, offering promising avenues for skin cancer management. Objective: This review aims to provide a comprehensive analysis of skin cancer pathogenesis and to evaluate the mechanistic insights and therapeutic potential of quercetinâalone and in nanoâformulated systemsâin preclinical models. The novelty of this review lies in its integrated approach, combining an overview of natural compound therapy with the latest cuttingâedge nanotechnology strategies to overcome current treatment challenges. Methods: This literature review was performed by searching related words, including âSkin cancer,â âMelanoma,â âBasal cell carcinoma,â âSquamous cell carcinoma,â âQuercetin,â âNanotechnology,â in different databases like Google Scholar, Scopus, PubMed, Web of Science, and Scientific Information Databases until 2025. Results: Preclinical studies indicate that quercetin modulates multiple cellular and molecular pathwaysâsuch as those regulating apoptosis, cell cycle progression, mitochondrial function, and DNA repairâto inhibit proliferation, migration, and invasion of skin cancer cells. Nanoâbased delivery systems (e.g., titanium dioxide nanoparticles, nanogels, and lipid carrier gels) have been shown to further enhance these therapeutic effects by improving quercetin's stability, skin permeability, and bioavailability. Conclusion: Integrating quercetin with nanoâbased formulations presents a novel and promising approach for targeted skin cancer therapy. While preclinical results are encouraging, further experimental and clinical investigations are necessary to fully validate these findings and facilitate translation into clinical practice.
- 28 February 2026
- Published by Wiley in Health Science Reports
- Vol. 9  (3)
Open AccessQuercetin and Its NanoâBased Formulations Against Skin Cancer: A Narrative Review
Background: Skin cancer is one of the most prevalent malignancies worldwide, characterized by the abnormal growth of skin cells and significant clinical challenges. Conventional treatmentsâincluding surgery, chemotherapy, and radiotherapyâoften suffer from limitations such as adverse side effects, tumor resistance, and inadequate efficacy. In this context, natural compounds have garnered attention as alternative therapeutic agents. Quercetin, a flavonoid widely distributed in fruits and vegetables, is recognized for its antiâcancer, antiâinflammatory, and antioxidant properties. However, its clinical application is hindered by poor solubility, low bioavailability, and limited skin permeation. Recent advances in nanotechnology have led to the development of nanoâbased formulations that can enhance the pharmacological performance of quercetin, offering promising avenues for skin cancer management. Objective: This review aims to provide a comprehensive analysis of skin cancer pathogenesis and to evaluate the mechanistic insights and therapeutic potential of quercetinâalone and in nanoâformulated systemsâin preclinical models. The novelty of this review lies in its integrated approach, combining an overview of natural compound therapy with the latest cuttingâedge nanotechnology strategies to overcome current treatment challenges. Methods: This literature review was performed by searching related words, including âSkin cancer,â âMelanoma,â âBasal cell carcinoma,â âSquamous cell carcinoma,â âQuercetin,â âNanotechnology,â in different databases like Google Scholar, Scopus, PubMed, Web of Science, and Scientific Information Databases until 2025. Results: Preclinical studies indicate that quercetin modulates multiple cellular and molecular pathwaysâsuch as those regulating apoptosis, cell cycle progression, mitochondrial function, and DNA repairâto inhibit proliferation, migration, and invasion of skin cancer cells. Nanoâbased delivery systems (e.g., titanium dioxide nanoparticles, nanogels, and lipid carrier gels) have been shown to further enhance these therapeutic effects by improving quercetin's stability, skin permeability, and bioavailability. Conclusion: Integrating quercetin with nanoâbased formulations presents a novel and promising approach for targeted skin cancer therapy. While preclinical results are encouraging, further experimental and clinical investigations are necessary to fully validate these findings and facilitate translation into clinical practice.
- Open Access
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026  (1)
The State of the Art in Septoplasty: A Review of the Latest Achievements
The deviated nasal septum is the most common cause of nasal airway obstruction, frequently diagnosed by otolaryngologists in clinical practice. Reports displayed that this condition affects 70%â80% of the population. The etiology of this upper airway problem is mainly related to intrinsic deformity or quadrangular cartilage dislocation from its bony borders, which can finally confer different disorders, such as breathing problems, sinus infections, snoring, headaches, exacerbating sleep apnea, and sleep disturbances. One of the most common methods for correcting a deviated nasal septum is septoplasty. However, this procedure still requires significant improvements to enhance its effectiveness and reduce the risk of surgeryârelated complications, particularly nasal septal perforation and the recurrence of deviation in adolescents and adults. In recent years, numerous strategies have been proposed to enhance septoplasty outcomes and reduce surgeryârelated complications. Many of these approaches focus on improving pain management, restoring olfactory function, alleviating symptoms, and enhancing clinical nasal outcomes. Additionally, they are aimed at promoting healing of the nasal mucosa and close septal perforations following surgery. This narrative review critically appraises the latest advancements in septoplasty, contrasting highâlevel evidence from large multicenter trials with promising but preliminary findings from novel techniques aimed at enhancing outcomes and reducing complications.
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026  (1)
Open AccessThe State of the Art in Septoplasty: A Review of the Latest Achievements
The deviated nasal septum is the most common cause of nasal airway obstruction, frequently diagnosed by otolaryngologists in clinical practice. Reports displayed that this condition affects 70%â80% of the population. The etiology of this upper airway problem is mainly related to intrinsic deformity or quadrangular cartilage dislocation from its bony borders, which can finally confer different disorders, such as breathing problems, sinus infections, snoring, headaches, exacerbating sleep apnea, and sleep disturbances. One of the most common methods for correcting a deviated nasal septum is septoplasty. However, this procedure still requires significant improvements to enhance its effectiveness and reduce the risk of surgeryârelated complications, particularly nasal septal perforation and the recurrence of deviation in adolescents and adults. In recent years, numerous strategies have been proposed to enhance septoplasty outcomes and reduce surgeryârelated complications. Many of these approaches focus on improving pain management, restoring olfactory function, alleviating symptoms, and enhancing clinical nasal outcomes. Additionally, they are aimed at promoting healing of the nasal mucosa and close septal perforations following surgery. This narrative review critically appraises the latest advancements in septoplasty, contrasting highâlevel evidence from large multicenter trials with promising but preliminary findings from novel techniques aimed at enhancing outcomes and reducing complications.
- Open Access
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026  (1)
Oxycodone: A PainâRelieving Agent With Cardioprotective Properties Against Myocardial IschemiaâReperfusion Injury
In the realm of cardiovascular diseases, myocardial ischemiaâreperfusion injury (MIRI) is known as one of the main lifeâthreatening conditions with significant morbidity and mortality. Although some therapeutic approaches, like pharmacological treatments and ischemic preconditioning, have been suggested for MIRI, offering a functional approach with high effectiveness for MIRI remains challenging. Recent studies have indicated that oxycodone, a semisynthetic opioid used to improve acute to chronic pain, may be cardioprotective against MIRI. The current experimental evidence showed that these protective influences can stem from the ability of oxycodone to regulate apoptosis, inflammation, and oxidative stress, as well as promote cardiovascular parameters (e.g., infarct size, cardiac function, and endothelial integrity). Hence, the main purpose of this narrative review study is to summarize and discuss the antiâMIRI potential of oxycodone with a mechanistic insight. This narrative review was also conducted to hold promise for researchers and clinicians to consider and assess its clinical capacity for subjects suffering from this challenging disease.
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026  (1)
Open AccessOxycodone: A PainâRelieving Agent With Cardioprotective Properties Against Myocardial IschemiaâReperfusion Injury
In the realm of cardiovascular diseases, myocardial ischemiaâreperfusion injury (MIRI) is known as one of the main lifeâthreatening conditions with significant morbidity and mortality. Although some therapeutic approaches, like pharmacological treatments and ischemic preconditioning, have been suggested for MIRI, offering a functional approach with high effectiveness for MIRI remains challenging. Recent studies have indicated that oxycodone, a semisynthetic opioid used to improve acute to chronic pain, may be cardioprotective against MIRI. The current experimental evidence showed that these protective influences can stem from the ability of oxycodone to regulate apoptosis, inflammation, and oxidative stress, as well as promote cardiovascular parameters (e.g., infarct size, cardiac function, and endothelial integrity). Hence, the main purpose of this narrative review study is to summarize and discuss the antiâMIRI potential of oxycodone with a mechanistic insight. This narrative review was also conducted to hold promise for researchers and clinicians to consider and assess its clinical capacity for subjects suffering from this challenging disease.
- Open Access
- 22 December 2025
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 20, 264-275
Therapeutic effectiveness of conditioned medium derived from adipose tissue mesenchymal stem cells and dehydroepiandrosterone in a rat model of spinal cord injury
- 22 December 2025
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 20, 264-275
Open AccessTherapeutic effectiveness of conditioned medium derived from adipose tissue mesenchymal stem cells and dehydroepiandrosterone in a rat model of spinal cord injury
- Open Access
- 3 November 2025
- Published by Springer Nature in Blood Research
- Vol. 60  (1) , 1-13
Unveiling the role of microRNAs, the PI3K/AKT pathway, and their associations in various types of leukemia: a comprehensive review
The phosphatidylinositol-3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway and microRNA (miRNA) regulation have been implicated in the initiation and progression of acute leukemia. Despite significant progress in the understanding of leukemogenic mechanisms, current therapies remain limited by relapse, drug resistance, and poor long-term survival, underscoring the need for novel targeted strategies. This review provides the current evidence regarding the molecular interplay between PI3K/AKT/mTOR signaling and miRNA dysregulation in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). We highlight key oncogenic and tumor-suppressive miRNAs, discuss their regulatory impact on critical genes (PIK3CA, AKT1, PTEN, and FMS-like tyrosine kinase 3 [FLT3]), and evaluate therapeutic approaches, including PI3K/AKT inhibitors and miRNA-based interventions. Furthermore, we identified existing controversies, methodological limitations, and unresolved research gaps. Finally, we emphasize the translational potential of miRNA-targeted therapies and pathway-specific inhibitors, providing insights into their integration into personalized treatment strategies for acute leukemia.
- 3 November 2025
- Published by Springer Nature in Blood Research
- Vol. 60  (1) , 1-13
Open AccessUnveiling the role of microRNAs, the PI3K/AKT pathway, and their associations in various types of leukemia: a comprehensive review
The phosphatidylinositol-3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway and microRNA (miRNA) regulation have been implicated in the initiation and progression of acute leukemia. Despite significant progress in the understanding of leukemogenic mechanisms, current therapies remain limited by relapse, drug resistance, and poor long-term survival, underscoring the need for novel targeted strategies. This review provides the current evidence regarding the molecular interplay between PI3K/AKT/mTOR signaling and miRNA dysregulation in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). We highlight key oncogenic and tumor-suppressive miRNAs, discuss their regulatory impact on critical genes (PIK3CA, AKT1, PTEN, and FMS-like tyrosine kinase 3 [FLT3]), and evaluate therapeutic approaches, including PI3K/AKT inhibitors and miRNA-based interventions. Furthermore, we identified existing controversies, methodological limitations, and unresolved research gaps. Finally, we emphasize the translational potential of miRNA-targeted therapies and pathway-specific inhibitors, providing insights into their integration into personalized treatment strategies for acute leukemia.